TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02805751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early loading on a training pedal
Description: The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tendon strain exercises
Description: The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tendon strain exercises
Description: The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early weight bearing
Description: The patients are allowed to bear weight as much as tolerated in the walker from day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early weight bearing
Description: The patients are allowed to bear weight as much as tolerated in the walker from day 1.
Study: NCT02645877

Intervention type: PROCEDURE
Intervention: Prehospital care
Description: The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
Study: NCT00882583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral Dasatinib Days 8 through 64.
Study: NCT04240002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granulocyte colony-stimulating factor (G-CSF)
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granulocyte colony-stimulating factor (G-CSF)
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granulocyte colony-stimulating factor (G-CSF)
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granulocyte colony-stimulating factor (G-CSF)
Description: Administered by subcutaneous injection
Study: NCT03712618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion - LONG Platelet Transfusion
Description: Platelets Transfused over 4-HOURS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion - LONG Platelet Transfusion
Description: Platelets Transfused over 4-HOURS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion - SHORT Platelet Transfusion
Description: Platelets Transfused within 60-minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion - SHORT Platelet Transfusion
Description: Platelets Transfused within 60-minutes
Study: NCT04429139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
Study: NCT02870296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Assessment and Education
Description: Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
Study: NCT00882583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral Dasatinib Days 8 through 64.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Q 3 weeks (Days 15, 36 and 57): +/- 3 Days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard Radiation Therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard Radiation Therapy.
Study: NCT02782052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide
Description: Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized combination ipratropium bromide with salbutamol
Description: Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized Placebo
Description: Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL).
Study: NCT02697227

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Receive BATS counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Receive nicotine patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Receive nicotine patch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention
Description: Receive standard smoking cessation counseling
Study: NCT03150966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Description: Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take placebo in the form of capsules daily during 6 months study period
Study: NCT05896098

Intervention type: OTHER
Intervention: Ultrasound
Description: Measurement of the airway by ultrasound in obese patients.

Intervention type: OTHER
Intervention: Ultrasound
Description: Measurement of the airway by ultrasound in obese patients.
Study: NCT00907608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
Study: NCT01224340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lollipop
Description: The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: serious games
Description: The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
Study: NCT00002705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study: NCT00185380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS (BAY86-5028, G04209B)
Description: Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS (BAY86-5028, G04209C)
Description: Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
Study: NCT03441997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mind-body exercise
Description: Exercise program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light mobility exercises
Description: Modified mind-body program.
Study: NCT03907865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Softacort
Description: Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Softacort
Description: Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
Study: NCT02589665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00978380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
Study: NCT01120236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03732495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + Denosumab
Description: Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met
Study: NCT04697082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma administration
Description: Platelet rich plasma (PRP) was administered by filling the whole space from the lateral side of the cavity. After the first implementation of PRP, the second one was applied at 48 hours. Until that time, the dressing was not uncovered. PRP was applied on the 3rd, 4th and 5th days postoperatively.
Study: NCT01683292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled VR040

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VR040
Description: Placebo arm
Study: NCT00922181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Liver tumors are destructed/ablated using single-probe microwave energy device
Study: NCT04639492

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MBS oral solution
Description: Oral BIDAC, twice a day before breakfast and dinner times
Study: NCT04581369

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care Coordinator Intervention for Direct Intervention Group
Description: The First Visit: The care coordinator will conduct a visit within 72 hours of hospital discharge to assess the patient's physical, cognitive, and psychological status, and will complete a needs assessment for both the patient and family caregiver. These measures will be used to guide the use of care protocols and development of the individualized care plan. The care plan will be developed with an emphasis on coordinating services with the patient's providers.~The Second Visit: During the second visit, the coordinator will review the individualized care plan with both the patient and the family caregiver and will make revisions to the plan based on assessment outcomes.~The 6-month Interaction Period: Approximately every 2 weeks, the coordinator will meet with the participant to revisit the care plan and to facilitate care.~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians.
Study: NCT00922181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Liver tumors are destructed/ablated using radiofrequency energy device
Study: NCT02612974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hirudinaria granulosa, qurse mafasil
Description: compare the efficacy of both groups

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hirudinaria granulosa, qurse mafasil
Description: compare the efficacy of both groups
Study: NCT02206334

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT
Study: NCT01573975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5RA-5RCM
Description: rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5RA-5RCT
Description: rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10RCA
Description: rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
Study: NCT02032810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
Study: NCT00112320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVR plus RV remodeling
Description: PVR and surgical RV remodeling, which includes bioprosthetic pulmonary valve insertion and resection of akinetic scarred areas on the anterior RV wall to reduce RV volume

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PVR
Description: PVR alone, which includes bioprosthetic pulmonary valve insertion and, when present, resection of right ventricular outflow tract (RVOT) aneurysm
Study: NCT01681225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esophageal-pressure guided mechanical ventilation
Study: NCT04194944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered IV
Study: NCT04581369

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Care Coordinator Intervention for Standard of Care Group
Description: For participants randomized to this arm, a consultation with the care team will be arranged prior to hospital discharge. Outcome measures will be obtained by blinded research staff from all enrolled subjects at baseline, 3 months, and 6 months. This is the extent of interventions received for participants in this arm.
Study: NCT03440450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10832 Gemcitabine Liposome Injection
Description: FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10832 Gemcitabine Liposome Injection
Description: FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10832 Gemcitabine Liposome Injection
Description: FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10832 Gemcitabine Liposome Injection
Description: FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10832 Gemcitabine Liposome Injection
Description: FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
Study: NCT04581369

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caregiver Intervention
Description: Caregivers of the participants will be assessed for caregiver burden at 3 time points.
Study: NCT01997216

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A multifocal contact lens
Description: Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
Study: NCT03156686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HOME-based hospitalization
Description: patients in Home care treatment (HC) group will be treated at home
Study: NCT04355442

Intervention type: PROCEDURE
Intervention: Facial fractures reduction or osteosynthesis
Description: Facial fractures reduction or osteosynthesis

Intervention type: PROCEDURE
Intervention: Facial fractures reduction or osteosynthesis
Description: Facial fractures reduction or osteosynthesis
Study: NCT03130621

Intervention type: DIAGNOSTIC_TEST
Intervention: Gene detection
Description: Next-generation sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: Gene detection
Description: Next-generation sequencing
Study: NCT00568373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra Gastric Pacemaker
Description: Gastric Pacemaker
Study: NCT02503358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO